Get started
Lyell Immunopharma, Inc.Lyell Immunopharma, Inc.Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

LYEL chart


Full chart

LYEL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪141.17 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.3120 USD
Net income (FY)
‪−342.99 M‬ USD
Revenue (FY)
‪61.00 K‬ USD
Shares float
‪124.88 M‬
Beta (1Y)
1.26

Employees


Employees (FY)
300
Change (1Y)
+76 +33.93%
Revenue / Employee (1Y)
203.33 USD
Net income / Employee (1Y)
‪−1.14 M‬ USD

About Lyell Immunopharma, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Lynn Seely
Website
lyell.com
Headquarters
South San Francisco
Founded
2018
FIGI
BBG00RNXFN14
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

LYEL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as LYEL.

Frequently Asked Questions


The current price of LYEL is 0.4625 USD — it has increased by 3.91% in the past 24 hours. Watch Lyell Immunopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lyell Immunopharma, Inc. stocks are traded under the ticker LYEL.
LYEL stock has risen by 8.81% compared to the previous week, the month change is a −18.19% fall, over the last year Lyell Immunopharma, Inc. has showed a −80.89% decrease.
We've gathered analysts' opinions on Lyell Immunopharma, Inc. future price: according to them, LYEL price has a max estimate of 1.00 USD and a min estimate of 0.60 USD. Watch LYEL chart and read a more detailed Lyell Immunopharma, Inc. stock forecast: see what analysts think of Lyell Immunopharma, Inc. and suggest that you do with its stocks.
LYEL reached its all-time high on Sep 7, 2021 with the price of 19.8400 USD, and its all-time low was 0.3931 USD and was reached on Apr 11, 2025. View more price dynamics on LYEL chart.
See other stocks reaching their highest and lowest prices.
LYEL stock is 6.71% volatile and has beta coefficient of 1.26. Track Lyell Immunopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Lyell Immunopharma, Inc. there?
Today Lyell Immunopharma, Inc. has the market capitalization of ‪141.17 M‬, it has decreased by −1.12% over the last week.
Yes, you can track Lyell Immunopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Lyell Immunopharma, Inc. is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
LYEL earnings for the last quarter are −0.70 USD per share, whereas the estimation was −0.17 USD resulting in a −314.71% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about Lyell Immunopharma, Inc. earnings.
Lyell Immunopharma, Inc. revenue for the last quarter amounts to ‪11.00 K‬ USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
LYEL net income for the last quarter is ‪−191.94 M‬ USD, while the quarter before that showed ‪−44.58 M‬ USD of net income which accounts for −330.51% change. Track more Lyell Immunopharma, Inc. financial stats to get the full picture.
No, LYEL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 300 employees. See our rating of the largest employees — is Lyell Immunopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lyell Immunopharma, Inc. EBITDA is ‪−204.26 M‬ USD, and current EBITDA margin is ‪−334.85 K‬%. See more stats in Lyell Immunopharma, Inc. financial statements.
Like other stocks, LYEL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lyell Immunopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lyell Immunopharma, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lyell Immunopharma, Inc. stock shows the sell signal. See more of Lyell Immunopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.